In recent years, with the discovery of the considerable therapeutic potential of cancer immunotherapy, researchers have developed new immune checkpoint targets, such as TIM3, lymphocyte activation gene 3 (LAG3), and tyrosine-based inhibition motif domain (TIGIT) [9]. The gene discussed is HAVCR2; the disease is cancer.